Suellen M. Curkendall
Research Subjects
Suellen M. Curkendall has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Dewei She
The EMMES Corporation
2 shared publications- Earl L. Goehring
Bausch Health Companies Inc, Bridgewater, USA
2 shared publications Judith K. Jones
The Degge Group, Ltd
2 shared publicationsMary Rose Stang
Saskatchewan Health
2 shared publicationsStephan Lanes
Boehringer-Ingelheim Pharmaceuticals, Inc
2 shared publicationsAe Fisher
Gilead Sciences, Foster City, CA, USA
1 shared publication
Latest Publications
- Open Access
- 29 September 2008
- Published by Wiley in Arthritis Care & Research
- Vol. 59 (10) , 1519-1526
Compliance with biologic therapies for rheumatoid arthritis: Do patient out‐of‐pocket payments matter?
Objective: To assess the impact of patient out‐of‐pocket (OOP) expenditures on adherence and persistence with biologics in patients with rheumatoid arthritis (RA).Methods: An inception cohort of RA patients with pharmacy claims for etanercept or adalimumab during 2002–2004 was selected from an insurance claims database of self‐insured employer health plans (n = 2,285) in the US. Adherence was defined as medication possession ratio (MPR): the proportion of the 365 followup days covered by days supply. Persistence was determined using a survival analysis of therapy discontinuation during followup. Patient OOP cost was measured as the patient's coinsurance and copayments per week of therapy, and as the proportion of the total medication charges paid by the patient. Multivariate linear regression models of MPR and proportional hazards models of persistence were used to estimate the impact of cost, adjusting for insurance type and demographic and clinical variables.Results: Mean ± SD OOP expenditures averaged $7.84 ± $14.15 per week. Most patients (92%) paid less than $20 OOP for therapy/week. The mean ± SD MPR was 0.52 ± 0.31. Adherence significantly decreased with increased weekly OOP (coeff = −0.0035, P < 0.0001) and with a higher proportion of therapy costs paid by patients (coeff = −0.8794, P < 0.0001), translating into ∼1 week of therapy lost per $5.50 increase in weekly OOP. Patients whose weekly cost exceeded $50 were more likely to discontinue than patients with lower costs (hazard ratio 1.58, P < 0.001).Conclusion: Most patients pay less than $20/week for biologics, but a small number have high OOP expenses, associated with lower medication compliance. The adverse impact of high OOP costs on adherence, persistence, and outcomes must be considered when making decisions about increasing copayments.
- 29 September 2008
- Published by Wiley in Arthritis Care & Research
- Vol. 59 (10) , 1519-1526
Open AccessCompliance with biologic therapies for rheumatoid arthritis: Do patient out‐of‐pocket payments matter?
Objective: To assess the impact of patient out‐of‐pocket (OOP) expenditures on adherence and persistence with biologics in patients with rheumatoid arthritis (RA).Methods: An inception cohort of RA patients with pharmacy claims for etanercept or adalimumab during 2002–2004 was selected from an insurance claims database of self‐insured employer health plans (n = 2,285) in the US. Adherence was defined as medication possession ratio (MPR): the proportion of the 365 followup days covered by days supply. Persistence was determined using a survival analysis of therapy discontinuation during followup. Patient OOP cost was measured as the patient's coinsurance and copayments per week of therapy, and as the proportion of the total medication charges paid by the patient. Multivariate linear regression models of MPR and proportional hazards models of persistence were used to estimate the impact of cost, adjusting for insurance type and demographic and clinical variables.Results: Mean ± SD OOP expenditures averaged $7.84 ± $14.15 per week. Most patients (92%) paid less than $20 OOP for therapy/week. The mean ± SD MPR was 0.52 ± 0.31. Adherence significantly decreased with increased weekly OOP (coeff = −0.0035, P < 0.0001) and with a higher proportion of therapy costs paid by patients (coeff = −0.8794, P < 0.0001), translating into ∼1 week of therapy lost per $5.50 increase in weekly OOP. Patients whose weekly cost exceeded $50 were more likely to discontinue than patients with lower costs (hazard ratio 1.58, P < 0.001).Conclusion: Most patients pay less than $20/week for biologics, but a small number have high OOP expenses, associated with lower medication compliance. The adverse impact of high OOP costs on adherence, persistence, and outcomes must be considered when making decisions about increasing copayments.
- 18 October 2007
- Published by Wiley in HIV Medicine
- Vol. 8 (8) , 483-490
Incidence of anaemia among HIV‐infected patients treated with highly active antiretroviral therapy*
Objective: The aim of the study was to compare the incidence of anaemia in patients treated with zidovudine (ZDV) with that in patients treated with highly active antiretroviral therapy (HAART) not including ZDV.Methods: Using HIV Insight, a database of abstracted US HIV care centre medical charts, ZDV‐naïve patients starting ZDV‐containing HAART were compared with those starting non‐ZDV, nucleoside reverse transcriptase inhibitor‐containing HAART. Cohorts were divided as follows: group 1: without baseline anaemia [haemoglobin (Hb) ≥11 g/dL]; group 2: with baseline anaemia (Hb P=0.005). In group 2, the ZDV/non‐ZDV risk ratio for worsening anaemia was 2.2 (95% confidence interval 1.1–4.3).Conclusions: Patients initiating ZDV‐containing HAART are at greater risk of developing new anaemia or worsening anaemia than patients initiating non‐ZDV‐containing HAART.
- 18 October 2007
- Published by Wiley in HIV Medicine
- Vol. 8 (8) , 483-490
Incidence of anaemia among HIV‐infected patients treated with highly active antiretroviral therapy*
Objective: The aim of the study was to compare the incidence of anaemia in patients treated with zidovudine (ZDV) with that in patients treated with highly active antiretroviral therapy (HAART) not including ZDV.Methods: Using HIV Insight, a database of abstracted US HIV care centre medical charts, ZDV‐naïve patients starting ZDV‐containing HAART were compared with those starting non‐ZDV, nucleoside reverse transcriptase inhibitor‐containing HAART. Cohorts were divided as follows: group 1: without baseline anaemia [haemoglobin (Hb) ≥11 g/dL]; group 2: with baseline anaemia (Hb P=0.005). In group 2, the ZDV/non‐ZDV risk ratio for worsening anaemia was 2.2 (95% confidence interval 1.1–4.3).Conclusions: Patients initiating ZDV‐containing HAART are at greater risk of developing new anaemia or worsening anaemia than patients initiating non‐ZDV‐containing HAART.
- 15 November 2006
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 21 (11) , 803-813
Chronic obstructive pulmonary disease severity and cardiovascular outcomes
To identify predictors of chronic obstructive pulmonary disease (COPD) severity and assess the relation between COPD severity and risk of cardiovascular outcomes. A␣cohort of patients with diagnosed and treated COPD was compiled from the Saskatchewan Health longitudinal databases. We used multivariate modeling to identify predictors of hospitalization for COPD as an indicator of COPD severity, and we used the model to characterize patients according to quintiles of COPD severity. These severity levels were used as independent variables in multivariate models of cardiovascular outcomes. Determinants of COPD severity included emphysema, recent nebulizer use, home oxygen services, corticosteroid use, frequent bronchodilator use, pneumonia and prior COPD exacerbation. The 20% of patients with the highest COPD severity were 1.27 (CI: 1.07–1.50) times more likely to have arrhythmia, 1.25 (CI: 1.07–1.46) times more likely to have ischemic heart disease, 1.38 (CI: 1.11–1.71) times more likely to have angina, 2.28 (CI: 1.95–2.66) times more likely to have congestive heart failure, and 1.63 (CI: 1.22–2.16) times more likely to die of cardiovascular causes than the least severe 20% of patients. Patients with more severe COPD, as defined by our model, had higher cardiovascular morbidity and mortality than patients with less severe COPD.
- 15 November 2006
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 21 (11) , 803-813
Chronic obstructive pulmonary disease severity and cardiovascular outcomes
To identify predictors of chronic obstructive pulmonary disease (COPD) severity and assess the relation between COPD severity and risk of cardiovascular outcomes. A␣cohort of patients with diagnosed and treated COPD was compiled from the Saskatchewan Health longitudinal databases. We used multivariate modeling to identify predictors of hospitalization for COPD as an indicator of COPD severity, and we used the model to characterize patients according to quintiles of COPD severity. These severity levels were used as independent variables in multivariate models of cardiovascular outcomes. Determinants of COPD severity included emphysema, recent nebulizer use, home oxygen services, corticosteroid use, frequent bronchodilator use, pneumonia and prior COPD exacerbation. The 20% of patients with the highest COPD severity were 1.27 (CI: 1.07–1.50) times more likely to have arrhythmia, 1.25 (CI: 1.07–1.46) times more likely to have ischemic heart disease, 1.38 (CI: 1.11–1.71) times more likely to have angina, 2.28 (CI: 1.95–2.66) times more likely to have congestive heart failure, and 1.63 (CI: 1.22–2.16) times more likely to die of cardiovascular causes than the least severe 20% of patients. Patients with more severe COPD, as defined by our model, had higher cardiovascular morbidity and mortality than patients with less severe COPD.
- Top Cited Papers
- 1 January 2006
- Published by Elsevier in Annals of Epidemiology
- Vol. 16 (1) , 63-70
Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease, Saskatchewan Canada
- 1 January 2006
- Published by Elsevier in Annals of Epidemiology
- Vol. 16 (1) , 63-70
Top Cited PapersCardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease, Saskatchewan Canada